Evaluation of mannitol effect in patients with acute hepatic failure and acute-on-chronic liver failure using conventional MRI, diffusion tensor imaging and in-vivo proton MR spectroscopy

Figure 2 Repeat MRI and DTI were performed after 30 min of mannitol infusion on the same ALF patient as in Figure 1 to look for any mannitol effect on imaging. In post-mannitol study, the effect of mannitol was quantified between 30-46 min. A: Axial T2-weighted image; B: Localized proton spectrum from the same region as in Figure 1A shows NAA/Cr = 1.83, Cho/Cr = 0.29, Gln/Cr = 2.60, Glx/Cr = 4.57, mI/Cr = 0.32; C: Mean diffusivity (MD) map, [anterior limb of internal capsule (ALIC) = 0.67, posterior limb of internal capsule (PLIC) = 0.70, caudate nuclei (CN) = 0.70, putamen (P) = 0.63, thalamus (TH) = 0.62, frontal white matter (FWM) = 0.66, occipital white matter (OWM) = 0.60, corpus callosum (CC) = 0.70, cingulum = 0.72, frontal cortex = 0.69, parietal cortex = 0.66, occipital cortex = 0.62]; D: Fractional anisotropy (FA) map, (ALIC = 0.32, PLIC = 0.34, CN = 0.08, putamen = 0.06, thalamus = 0.13, FWM = 0.30, OWM = 0.43, CC = 0.46, cingulum = 0.40, frontal cortex = 0.10, parietal cortex = 0.12, occipital cortex = 0.08) at the level of third ventricle. E: There is no significant change in the MD and FA values, and metabolite ratios mentioned here compared to what is mentioned in Figure 1. Cho: Choline; Cr: Creatine; Gln: Glutamine; Glx: Glutamine/glutamate; mI: Myoinositol; NAA: N-acetylaspartate.